ZYNE Zynerba Pharmaceuticals Inc.

5.7
0  0%
Previous Close 5.7
Open 5.75
Price To Book 1.56
Market Cap 132,228,657
Shares 23,198,010
Volume 743,461
Short Ratio
Av. Daily Volume 592,458
Stock charts supplied by TradingView

NewsSee all news

  1. Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome

    DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  2. Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

    DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  3. Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

    DEVON, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  4. Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

    - Positive Topline Results from BELIEVE 1 Phase 2 Trial of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies Suggest Compelling Seizure Reductions and Excellent Tolerability - -

  5. Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

    DEVON, Pa., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 trial failed to meet target blood levels. Company to focus on ZYN002.
ZYN001
Healthy volunteers
Development to be discontinued - noted January 2018.
ZYN001
Fibromyalgia
Development to be discontinued - noted January 2018.
ZYN001
Peripheral Neuropathic Pain (PNP)
Phase 2/3 data due 2Q 2020.
Zygel ZYN002
Fragile X syndrome
Phase 2 data released August 14, 2017 - primary endpoint not met. Noted January 2018 that development will be discontinued.
ZYN002 - STOP
Osteoarthritis
Phase 2b trial initiation postponed until after the completion of childhood neuropsychiatric studies.
ZYN002
Adult Epilepsy Patients with Refractory Focal Seizures
Phase 2 top-line data released September 18, 2019. 10/46 patients reported a serious adverse event (SAE).
ZYN002 BELIEVE 1
Developmental and Epileptic Encephalopathies (DEE)
Phase 2 data due 2Q 2020.
Zygel ZYN002
22q11.2 Deletion Syndrome
Phase 2 data due 2Q 2020.
Zygel ZYN002 - BRIGHT
Autism Spectrum Disorder (ASD)

Latest News

  1. Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome

    DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  2. Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

    DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  3. Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

    DEVON, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  4. Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

    - Positive Topline Results from BELIEVE 1 Phase 2 Trial of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies Suggest Compelling Seizure Reductions and Excellent Tolerability - -

  5. Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

    DEVON, Pa., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  6. Zynerba Pharmaceuticals, Inc. Presenting at the Benzinga Cannabis Capital Conference in Chicago

    Chicago, Illinois--(Newsfile Corp. - October 15, 2019) - Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), will be presenting at the 5th Benzinga Cannabis Capital Conference in Chicago October 22-23 before an audience of

  7. Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    DEVON, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  8. Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)

    - Study Achieves a 44% Median Seizure Reduction in Focal Impaired Awareness (Complex Partial) and Convulsive Seizures in DEE Patients by Month Two; Reductions were Sustained through Month Six of Treatment with Zygel - -

  9. Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms

    - Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behavioral Symptoms Associated with these Conditions – - New Data Presented Today at the Society for the Study of Behavioural

  10. New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

    - Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS - - New Data Presented Today at the Society for the Study of Behavioural

  11. New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

    - Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS - - New Data Presented Today at the Society for the Study of Behavioural

  12. Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

    DEVON, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  13. Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium

    DEVON, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric